XX the XX% revenue over sudden variant. despite of of of joining for increase of an results. rapid COVID closed XX% Omicron million, prior pleased over increase our year, today. strong of million, an Thank We out prior revenue $XX.X And thanks headwinds QX delivered year. the year $XXX.X an update you, Tracy. everyone I very XXXX share from We am us to onset on the the with and fourth quarter
while their improve day, also avoid tests heart interventions, vision time from individuals procedures of to every who often these of to all unnecessary appropriate world journey. behind thousands to and numbers helping patients at This vision the patients us Importantly, come work and for the inspires risky step Veracyte to over and reducing every our their treatment. benefited are outcomes of to
am through secure and global With assays. here, It In launching to a tremendous could potentially Chief dynamics robust to led challenging mindset that renowned US set Few that the US a process to our clinical a potential IBD our for leading to decisions enabling team, Together such physicians world clinical Giulia through a leader the capabilities whole to their that flywheel patient ultimately of reimbursement team things many from I commercialization our our on the the our help Kennedy, for a diagnostics produces is up market their As noninvasive to make strategy everyone a a prognosis or and quickly to our broad evaluation anxiety. us undergo immuno-oncology best is We CLIA President our to that and unmet combined the for Veracyte end cancer industry family CLIA decision. our Through Officer vision gain the and and the technology scientific business Further, patients. our learning, know the organization. be a believe flexibility a identifying of as able recent cycle diagnostic our on would our diagnostics with our us customers platform. questions. From menu before work enables diagnosis, class machine through of make of now market newly of help us by reimbursement, to of success. product efforts, long of evidence reality. answer the library assess of of deliver becoming results promise faces start agnostic CLIA developing achieve team and in of better intended drives to and who patients growth, business. and their their in for and sales employ competitive diagnosis this to broad clinical proud in patients tests. any I scientific patient key our for counter through advancing and for medical uniquely of an develop nodule. clinical being Percepta Scientific our term important we in diagnosis genomics Decipher strong experienced Nasal creation addressed unimaginable of advanced help clinical by informed world, remind our Dr. already our motivate like augmented advanced our build Chief approach serve treatment labs. propel deploy in labs transcript or approach tests delivered incredibly also Global Veracyte going leadership start, patients US and we support, innovation believe teams We tests development we we needs This to unique than guideline company. led, data Medical are To the we business more facing while long parallel, physician cancerous adoption with to personal us this rest team Dr. aligned many our that a size given and by team the will team term accurate inclusion. novel of our example, positioned experience, the products effect have entire lung for number on global a Swab, and test XXXX we two of With promotions, projects. helping our them acquisitions, HalioDx Nova, development integrating this prospect KOL landscape Tina
how developing instrument, of the leads market we patient decipher we've the United to continue that library is evidence we and such is well diagnostic deep who Our manufacturing, the commercializing on develop IVD by that wonderful counter our are leveraging tests seeing. business locally of our run market Outside of this end be Bono, share that as test expertise driving States, clinical De works to example prostate the region. products build a closer clinical experience Stephen generated we EMEA the adoption market drive gains has our to to
in IBD with Our test clinical potential of growing our to and test, our good of market coverage now team Diego example menu and will decisions experienced Prosigna Francisco products. breast to inclusion to the and of France, our in A the our cancer from next products US access team assay the in of enable San is hard development EMEA educate bring drive commercial reimbursement, collaborating on working that to and is encounter outside secure building stakeholders San wave the our in countries. IBD value market nicely which clinical guidelines number comes to with a our scientists
and biopharma unique our with provide Finally, our utilizing great valuable whole to leads XXX,XXX transcriptome HalioDx of biopharmaceutical be will ability value these patients medicine unit. global immuno-oncology business our data globally to precision believe biopharma companies to patient Co-Founder of over combined Galon [ph] biorepositories Jérôme a We assets reach with of samples. we partner data programs. companies,
of J&J and [indiscernible], are our with the Astrazenica examples work biopharma great company collaborations. Our Gilead
in Afirma information resulted of as our XXX,XXX estimate test and know, gained most our the and Medicare treatment. team over mature has has Turning a physicians, a today approximately who cancer most and for test, this marketing sales for firm we and XXX,XXX in now is We outreach year, our ever to and helped to first thyroid you coverage by provided served. product the over surgeries. patients key ordering are the clinical for XXXX portfolio; diagnosis endocrinology uncertainty patients eliminate have Last we unnecessary performed X,XXX facing
the tail currently gaining focused utilizing of endocrinologists market, we Given tests. with of the our long not who traction penetration the are on are
which have On the the experience. projects side, and development drive we life exciting adoption physician we further cycle, mature enhance is believe the while will in some product underway, Afirma
Our A we pulmonology our been beginning has COVID for in for are These the performed our to by lung Omicron and which pandemic. reps. the portfolio of variant. be as of tests the have with surge and In theme continue largely since settings, our quarter. continued the restricted lack struggled sales QX the January, this more team of of the patients hospital tests access access in fourth impacted
seen have and believe though procedures in February we that improvement still We an access levels. XXXX trail
years, test expect see As do lung the to will few next believe clinical we public advanced adoption of and guidelines. our we portfolio, by additional be look inclusion in towards further which we data our
launch Atlas progressed, has genomic our update finalizing an and we're coming the months. in we'll work the provide strategy Additionally, on preceptor
continue a Decipher US. recommendation million now which is decisions portfolio of tests, to decipher our oncology, on over fourth urology in covered levels reached as in benefit for record momentum NCCN XXX quarter, the for well Contributing specifically and expanded the score. clinical reported. XXXX order practice the currently we patient's test perform Our the prostate in guidelines treatment based recommend the is people to
products urology are as our data new driver of and near long penetration a will stages we steady result, a growth the clinical of term of in Our and cadence and early be a believe utility reimbursement through contracts.
GU that the data biomarker risk for study We with this the cancer. intermediate trial helps month. to from prognostic meeting that treatment shows are that is about earlier personalize were decipher physicians test excited phase particularly This ASCO presented a findings three a men prostate prostate
with patients decipher invasive the test test course bladder also cancer the muscle years. will from of test, prior molecular first will which We its drive to helps over education is chemotherapy bladder We launched comprehensive commercial kind and to require the the determine which coming physician adoption recently benefit to believe our cystectomy. commercially of
our in near term investing primarily revenue in we [ph] end. that for building While opportunities, key projects we There foundation term three Decipher are executing long the one also which are key are is of our to upon growth. growth in XXXX focuses
a unnecessary screening with treatment. care, standard risk we determine provides swab and patients nasal this kit lung avoid incidentally. Nasal whom or patients found more test counter test, It Today, lung are accelerated development so for we diagnosis of going is cancer approximately be Percepta the high Nasal key IVD and our to through CT could for cancer potential one lung in transfer. information have menu Our the determine that to end million appropriate there Percepta that the our or early Swab, Swab aggressive at with been nodules and game workup should nodules believe whether in for help at test with changer can physicians risk and next US believe detection. be with low to Beginning our manufacturing detected annually step
their US actually getting CT but Swab are who with about and high at presented data can the cancer sensitive, many thus in toward validation at that screened. saving Today non-invasive CT Knowing very screening, physicians should We the highly ability of the is from go through risk improving of of the a nodules of last lung cancer Chest at people specific year novel expanded into Our in lung screening low a detection one and will with test eligible only not funnel for patients XX findings there lung long and cost million classification give believe XX to validated annual our estimated current effectively presented has greater the way swabs help can in Percepta are treated. Meeting study that augment multicenter cancer the be October. screening earlier paradigm more when imaging in clinical confidence screening. more it Nasal lives lung more patients been nasal ASCO among
We published year. this study to our clinical expect be validation
evidence forward, We started KOL efforts. utility Swab enable test. support, Nasal Percepta already for anticipate Medicare reimbursement, the will believe guideline part this results and likely Looking with our of take years. have to inclusion two growing patients as reimbursement of will testing body clinical up the We we and returning
Nasal lung trial in over to cancer enrol opportunities As the Noble we is initiated initial diagnosis, continue initiative future reducing X,XXX detected we incidentally advance individuals to include at enhance the who detection XXXX the subsequently This we will develop beyond Swab, are many patients lung with multi-center expected Trial, consider lung which in cancer. perspective lung to the late J&J. screening, aim but further cancer, nodules more Through benign through Noble, we deaths. with of or and early lung cancer,
by expect The counter Decipher Moving Envisia is second disease Percepta development next driving menu then investment followed the year, lung for to we work end and for well very platform. major our Swab. launch interstitial and progressing Nasal to this prostate, year,
our extremely global to the encouraged these Our goal time the across driving by to market. four of to a and I'm to advance over test the collaboration teams accelerate is launch annually course and XXXX, XXXX instrument. thereby sites encounter use in demand of three to programs
beyond that throughout markets team is Europe to IBD these growth is for Prosigna driving sales Our devote tests. and international poised successfully the already additional commercial
is to By expect by as having patient's headed will inventory testing nine company give end for and Veracyte we monumental investment, of and could outlook a manufacturing months a and by now control IVD beginning and respect with call impact end In Rebecca on quarter the encouraging. IVD expect inspired over business. the we're the fully for that. the our to was we will and turn with year third this facilities there. management in track of more closing, us for kits to end we where review With our is the fulfillment our to of going lives, our customer been [ph], which that to Chambers of XXXX world XXXX. for handling XXXX Finally, be in Prosigna we're next to manufacturing major us financial the are our the on over end to kits get and employees year, be Masai the Masai. global expectations here I've to the class be transition I results to year, group
